Publications Repository

Publications Repository

View Item 
  •   Home
  • ICR Divisions
  • Other ICR Research
  • View Item
  • Home
  • ICR Divisions
  • Other ICR Research
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Thalidomide is highly effective in a patient with meningeal acute myeloid leukaemia

Thumbnail
Publication Date
2004
ICR Author
Baird, Richard
Duddy, James
Type
Journal Article
Metadata
Show full item record
Abstract
Thalidomide is highly effective in a patient with meningeal acute myeloid leukaemia. We report a case of secondary acute myeloid leukaemia (AML) following high dose therapy for diffuse large B-cell non- Hodgkin's lymphoma (NHL) who developed meningeal leukaemia. This was refractory to systemic and intrathecal chemotherapy and cranial irradiation. Thalidomide has been reported to have anti-AML activity and appears to cross the blood brain barrier (BBB). We, therefore, attempted a trial of oral Thalidomide and achieved rapid biochemical and cytological remission with a short course. The patient, however, progressed systemically and succumbed to her illness.
URL
https://repository.icr.ac.uk/handle/internal/1914
Collections
  • Other ICR Research
Subject
acute myeloid leukaemia (AML) meningeal myelodysplasia non- Hodgkin's lymphoma (NHL) thalidomide acute myelogenous leukemia lymphoid malignancies brain transplantation myelodysplasia therapies
License start date
2004
Citation
LEUKEMIA & LYMPHOMA, 2004, 45 (1), pp. 179 - 181

Browse

All of ICR repositoryICR DivisionsIssue dateAuthorsTitlesSubjectsThis collectionIssue dateAuthorsTitlesSubjects

Statistics

Most popular itemsStatistics by countryMost popular authors
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.